Coherus BioSciences, Inc. /
Surface Oncology, Inc.
Coherus BioSciences completes Surface Oncology acquisition
What happened
Coherus BioSciences, Inc. completed its acquisition of Surface Oncology, Inc. on Sept. 8, 2023. Surface is a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment.
The transaction’s total value was approximately $66.9 million, including $40 million plus Surface’s net cash at closing of $26.9 million. Surface shareholders also received contingent value rights tied to certain sales milestones and licensing payments.
The source
Everything on this page comes from the source below.
Coherus BioSciences completes Surface Oncology acquisition
This document is the source for the companies, stage, figure and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Closed
The source this page is built from.
Published by the source
The source this page is built from.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request accessAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly